Q-omics provides the consensus-scored UBE3C profile across patient tissues and cancer cell-line models. UBE3C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, UBE3C is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, UBE3C RNA expression shows 19,523 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where UBE3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE3C survival associations across molecular data types. UBE3C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE3C RNA expression–survival associations across cancer types. High UBE3C expression shows unfavorable associations in CESC, BLCA, LGG, PAAD and ACC, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for UBE3C RNA expression.
This table summarizes UBE3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UBE3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE3C shows higher tumor expression in HNSC, COAD, LIHC, KIRP, LUSC and LUAD. The HNSC box plot shows higher UBE3C RNA expression in tumor versus normal tissue (log2 FC = +0.770, t-test p < 0.001).
This table shows molecular features associated with UBE3C in patient tissues and cancer cell lines. In patient samples, UBE3C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
